CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TRATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONSDevelopment Agreement • January 28th, 2005 • Threshold Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS AGREEMENT is entered into as of the 30th day of November, 2004, (“Effective Date”) by and between THRESHOLD PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 951 Gateway Blvd., Suite 3A, South San Francisco, CA 94080, U.S.A. (“Threshold”), and MEDIBIC CO., LTD., a Japan corporation, having its head office at Daido Seimei Kasumigaseki Building 8F, 1-4-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan (“MediBIC”).
Yasuhiro Hashimoto, M.D. President and CEO MediBIC Co., Ltd. Daido Seimei Kasumigaseki Building 8FThreshold Pharmaceuticals Inc • January 28th, 2005 • Pharmaceutical preparations
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. AgreementThreshold Pharmaceuticals Inc • January 28th, 2005 • Pharmaceutical preparations • Delaware
Aziende Chimiche Riunite Angelini Francesco – Acraf S.p.a., having its registered office in Viale Amelia, 70—00181 Rome Italy c.f.01312320680, p.Iva 049290810000 a company incorporated under the laws of Italy (hereinafter referred to as “Acraf”)
